A Prospective International Multicenter Phase II Study to Evaluate the Efficacy, Safety and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Previous Therapy With Checkpoint Inhibitor Treatment
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2018
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms IO-PAZ
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 18 May 2018 Planned End Date changed from 28 Jan 2021 to 26 Feb 2021.
- 18 May 2018 Planned primary completion date changed from 28 Jun 2019 to 29 Jul 2019.
- 25 Mar 2018 Planned End Date changed from 3 May 2018 to 28 Jan 2021.